Overall survival and patient-reported outcome results from the placebo-controlled randomized phase III IMagyn050/GOG 3015/ENGOT-OV39 trial of atezolizumab for newly diagnosed stage III/IV ovarian cancer

Sandro Pignata, Michael A. Bookman, Jalid Sehouli, Austin Miller, Richard T. Penson, Çağatay Taşkıran, Charles Anderson, Sakari Hietanen, Tashanna Myers, Radosław Mądry, Lyndsay Willmott, Alain Lortholary, Jessica Thomes-Pepin, Carol Aghajanian, Carolyn K. McCourt, Ashley Stuckey, Xiaohua Wu, Shin Nishio, Larry J. Copeland, Yvette He, Luciana Molinero, Sheetal Patel, Yvonne G. Lin, Victor K. Khor, Kathleen N. Moore